129 related articles for article (PubMed ID: 30408244)
1. Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer.
Dearden L; Shalet N; Artenie C; Mills A; Jackson C; Grant L; Gater A
Eur J Cancer Care (Engl); 2019 Jan; 28(1):e12949. PubMed ID: 30408244
[TBL] [Abstract][Full Text] [Related]
2. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
[TBL] [Abstract][Full Text] [Related]
3. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
Ternov KK; Sønksen J; Fode M; Lindberg H; Kistorp C; Bisbjerg R; Faber J; Klausen TW; Palapattu G; Østergren PB
Eur J Cancer; 2022 Aug; 171():75-84. PubMed ID: 35709600
[TBL] [Abstract][Full Text] [Related]
4. Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis.
Cassinello J; Domínguez-Lubillo T; Gómez-Barrera M; Hernando T; Parra R; Asensio I; Casado MA; Moreno P
Cancer Treat Rev; 2021 Feb; 93():102152. PubMed ID: 33486302
[TBL] [Abstract][Full Text] [Related]
5. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
[TBL] [Abstract][Full Text] [Related]
6. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
7. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
8. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
[TBL] [Abstract][Full Text] [Related]
9. Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan.
Miyake H; Hara T; Terakawa T; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Apr; 15(2):313-319. PubMed ID: 27424256
[TBL] [Abstract][Full Text] [Related]
10. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Khalaf DJ; Sunderland K; Eigl BJ; Kollmannsberger CK; Ivanov N; Finch DL; Oja C; Vergidis J; Zulfiqar M; Gleave ME; Chi KN
Eur Urol; 2019 Jun; 75(6):940-947. PubMed ID: 30591354
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
15. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
[TBL] [Abstract][Full Text] [Related]
16. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
Thiery-Vuillemin A; Hvid Poulsen M; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Antoni L; Lukac M; Van Sanden S; Pissart G; Reid A
ESMO Open; 2018; 3(5):e000397. PubMed ID: 30116592
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
19. Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
Ternov KK; Nolsøe AB; Bratt O; Fode M; Lindberg H; Kistorp C; Palapattu G; Klausen TW; Sønksen J; Østergren PB
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):948-961. PubMed ID: 33820951
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]